David Kalergis

From Wikipedia, the free encyclopedia

David Kalergis (born December 9, 1948) is an American life sciences entrepreneur and the Co-founder, Chairman and Chief Executive Officer of Diffusion Pharmaceuticals Inc, a Charlottesville, Virginia, U.S.-based biotechnology and pharmaceutical company.[1] He co-founded the company in 2001 with American chemical engineer John L. Gainer. Kalergis became Diffusion's CEO in 2004, a position in which he has drawn extensively on his career in law, business, and clinical trials implementation.[2] Under Kalergis' leadership, Diffusion Pharmaceuticals has been cited for advancing improved cancer treatments and is currently conducting multicenter clinical trials of a novel therapeutic for brain cancers, including glioblastoma multiforme.[3][4][5][6] Diffusion Pharmaceuticals is also currently conducting clinical trials for the treatment of oxygen deficiencies associated with COVID-19 and acute stroke.[7]

David Kalergis

Education and career[]

Kalergis received a B.A. degree in Psychology in 1970 and J.D. and M.B.A. Degrees in 1982 from the University of Virginia. He subsequently worked with the New York-based law firm Dewey, Ballantine, Bushby, Palmer & Wood, maintaining that association until 1986, when he became President and General Counsel of Designs Import/Export, Ltd. From 1991 to 1997, he was Consultant, Director of Business Development, and General Counsel to the contract research organization Pharmaceutical Research Associates (PRA), Inc.[1][8] While with PRA, he was involved in numerous pharmaceutical development projects through the pre-clinical, clinical, and post-marketing stages.

In 1998 Kalergis was appointed Director of University of Virginia Gateway, a program to establish stronger ties between industry and academia, particularly in the area of life sciences.[1] His efforts have been cited in advancing relationships between the high-technology business and academic sectors, both regionally [9] and internationally.[10] It was through his association with the University of Virginia that Kalergis met Gainer, who was at that time a Professor of Chemical Engineering, leading to their collaboration in the founding of Diffusion Pharmaceuticals.

Kalergis also attended the Harvard Business School's Leadership and Strategy in Biotechnology and Pharmaceuticals program.[8]

Other activities[]

Kalergis is a founding director of publicly traded Virginia National Bank where he was Chairman of the Assets and Liabilities Committee and a member of the Audit Committee. He is a former member of the Boards of Directors of the Virginia Biotechnology Association, the Virginia Piedmont Technology Council, and the Computers4Kids Program in Charlottesville, Virginia. He is a member of the New York and Virginia State Bar Associations.[1][8]

Awards and books[]

Kalergis received the Virginia Piedmont Technology Council's Navigator award in 2002.[8] His and Gainer's work at Diffusion Pharmaceuticals was acknowledged in 2012, when the company received the Virginia Healthcare Innovators "Medical Product or Device" award.[11]

Kalergis is the author of The Role of the University in the Commercialization of Biotechnology (1981).[2]

References[]

  1. ^ a b c d "David Kalergis". Walker Research. Retrieved November 26, 2012.
  2. ^ a b "David Kalergis". Forbes. Archived from the original on January 23, 2013. Retrieved November 27, 2012.
  3. ^ "Two local firms head to clinical trial stage for cancer treatment medications". The Daily Progress. February 20, 2012. Retrieved December 15, 2012.
  4. ^ "Area biotech groups lead the charge". The Daily Progress. February 23, 2012. Retrieved December 15, 2012.
  5. ^ "Company Overview of Diffusion Pharmaceuticals LLC". Bloomberg Businessweek. Retrieved November 10, 2012.
  6. ^ "Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) With Concomitant Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM)". ClinicalTrials.gov. November 2011. Retrieved September 18, 2012.
  7. ^ "Diffusion Pharmaceuticals Announces FDA Accelerated Review of TSC Clinical Development Plan to Treat COVID-19 Patients with ARDS". Diffusion Pharmaceuticals. May 5, 2020. Retrieved May 25, 2020.
  8. ^ a b c d "Executive Profile: David G. Kalergis J.D., MBA". Bloomberg Businessweek. Retrieved November 26, 2012.
  9. ^ "Virginia Gateway in the news". Gateway. 1999. Archived from the original on April 28, 2004. Retrieved December 15, 2012.
  10. ^ "U.Va. building Japanese partnerships Patent Foundation opens licensing office in Kobe". InsideUVA. January 18–24, 2002. Archived from the original on December 29, 2011. Retrieved December 15, 2012.
  11. ^ "Diffusion Pharmaceuticals Wins 2012 VA Healthcare Innovators Award". Virginia Biotechnology Association. Archived from the original on January 13, 2013. Retrieved October 30, 2012.
Retrieved from ""